Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3… Dec 3, 2021
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia Dec 2, 2021
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360… Dec 1, 2021
Pharmadrug Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of Its… Nov 30, 2021
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin Nov 30, 2021
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical… Nov 30, 2021
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent… Nov 30, 2021
